The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2020 | ERIC recommendations on TP53 mutation classification
Paolo Ghia, MD, of the Università Vita-Salute San Raffaele, Milan, Italy, discusses the significance TP53 mutation status on chronic lymphocytic leukemia (CLL), as evaluated by a multicenter ERIC study comparing methods used for identifying the presence of TP53 mutations in CLL. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).
